Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma

• DOI: 10.1007/s00330-022-08980-4
• Publication Date: 2022-07-21T18:02:49Z
• Authors: Bang-Bin Chen; Po-Chin Liang; Tiffany Ting-Fang...; Tsung-Hao Liu; Ying-Chun Shen; Li-Chun Lu; Zhong-Zhe Lin; Chiun Hsu; Chih-Hung Hsu; Ann-Lii Cheng; Yu-Yun Shao
• Keywords: 2. Zero hunger; Sarcopenia; Carcinoma, Hepatocellular; Liver Neoplasms; Prognosis; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Humans; Obesity; Immunotherapy; Muscle, Skeletal; Retrospective Studies

To investigate the association of sarcopenia, myosteatosis, and sarcopenic obesity with survival outcomes among patients who underwent immunotherapy for advanced hepatocellular carcinoma (HCC).In this retrospective analysis, patients who initiated immunotherapy for advanced HCC were enrolled. Sarcopenia and myosteatosis were evaluated on pretreatment CT at L3 level by skeletal muscle index and mean muscle attenuation using predefined cutoff values. Sarcopenic obesity was defined as concurrent sarcopenia and body mass index > 25 kg/m2. The log-rank test and the Cox proportional hazards model were used to compare overall survival (OS) and progression-free survival (PFS).A total of 138 patients was included (discovery cohort n = 111, validation cohort n = 27). In the discovery cohort, patients with sarcopenia exhibited significantly poorer PFS (p = 0.048) and OS (p = 0.002) than patients without sarcopenia. Patients with myosteatosis exhibited significantly poorer PFS (p < 0.001) and OS (p < 0.001) than patients without myosteatosis. Patients with sarcopenic obesity compared to patients without sarcopenic obesity exhibited significantly poorer OS (p = 0.006) but not PFS (p = 0.31). In multivariate analysis adjusting for patient demographics, tumor extent, and liver function reserve, myosteatosis remained an independent predictor of poor PFS (p = 0.014) and OS (p = 0.007); sarcopenia remained an independent predictor for poor OS (p = 0.007). The prediction models for survival outcomes built by the discovery cohort showed similar performance in the validation cohort.Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC.• Sarcopenia and myosteatosis can be evaluated by CT at L3 level. • Sarcopenia, myosteatosis, and sarcopenic obesity were associated with poor survival outcomes in patients who underwent immunotherapy for advanced HCC. • Myosteatosis was an independent predictor of PFS and OS, and sarcopenia was independent for OS in these patients.